Please enable JavaScript.
Coggle requires JavaScript to display documents.
Plasma Renin Activity and Aldosterone Concentrations in Hypertensive Cats…
Plasma Renin Activity and Aldosterone Concentrations in Hypertensive Cats with and without Azotemia and in Response to Treatment with Amlodipine Besylate
-
-
The Study
hypothesis
-
The hypothesis: Based on the previously identified finding of significantly lower plasma potassium concentrations in cats with systemic hypertension, it was hypothesized that nonazotemic and azotemic cats with systemic hypertension would have significantly increased PAC that was driven by increased PRA.
-
-
-
-
aims
evaluate the effect of the first-line antihypertensive agent, amlodipine besylate, on PAC and PRA.
perform a cross-sectional analysis of PRA, PAC after solvent extraction from feline plasma and resuspension in human matrix, and aldosterone-to-renin ratios (ARR) in cats with variable renal function and in the pathogenesis of systemic hypertension
Results
-
in cats with comparable renal function (azotemia), aldosterone (PAC) was increased in both normotensive and hypertensive cats.
-
limitations
-
Cats treated with the dihydropyridine calcium channel blocker, amlodipine besylate, showed a significant CVs for the PRA assay were higher than ideal in this study and it is possible that using a smaller volume of plasma than advocated by the manufacturer contributed to these results
-
Antihypertensive therapy
-
Amlodipine besylate
-
a dihydropyridine calcium channel antagonist, has been established as the first-line antihypertensive agent for cats. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance
-